In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 6, 2009, Pages 634-642

  Goel, A ^a   Mittal, A ^a   Evstatiev, R ^b   Nemeth, M ^b   Kruis, W ^c   Stolte, M ^d   Boland, C R ^a   Gasche, C ^b,e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Evangelisches Krankenhaus Kalk   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e KIM3/Gastroenterologie ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APC; DINUCLEOTIDE; MESALAZINE; MUTAFLOR; NUCLEOTIDE; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DISEASE DURATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESCHERICHIA COLI; FEMALE; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MARKER GENE; MICROSATELLITE INSTABILITY; NUCLEOTIDE REPEAT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; COLITIS, ULCERATIVE; COLON; DOUBLE-BLIND METHOD; ESTRANES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MESALAMINE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; NITRILES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949218901     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04076.x     Document Type: Article

References (34)

1. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008 14 : 265 74.
2. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004 287 : G7 17.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997 386 : 623 7.
4. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998 58 : 5489 94.
5. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991 51 : 3075 9.
6. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003 100 : 776 81.
7. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998 58 : 5248 57.
8. Jung B, Doctolero RT, Tajima A, et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 2004 126 : 654 9.
9. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995 268 : 1336 8.
10. Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000 47 : 43 9.
11. Suzuki H, Harpaz N, Tarmin L, et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res 1994 54 : 4841 4.
12. Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996 56 : 1237 40.
13. Cravo ML, Albuquerque CM, Salazar de SL, et al. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. Am J Gastroenterol 1998 93 : 2060 4.
14. Park WS, Pham T, Wang C, et al. Loss of heterozygosity and microsatellite instability in non-neoplastic mucosa from patients with chronic ulcerative colitis. Int J Mol Med 1998 2 : 221 4.
15. Noffsinger AE, Belli JM, Fogt F, Fischer J, Goldman H, Fenoglio-Preiser CM. A germline hMSH2 alteration is unrelated to colonic microsatellite instability in patients with ulcerative colitis. Hum Pathol 1999 30 : 8 12.
16. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000 60 : 4864 8.
17. Gasche C, Chang CL, Rhees J, Goel A, Boland CR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 2001 61 : 7444 8.
18. Chang CL, Marra G, Chauhan DP, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002 283 : C148 54.
19. Campregher C, Luciani MG, Gasche C. Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut 2008 57 : 780 7.
20. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 100 : 1345 53.
21. Gasche C, Chang CL, Natarajan L, et al. Identification of frame-shift intermediate mutant cells. Proc Natl Acad Sci U S A 2003 100 : 1914 9.
22. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005 65 : 3993 7.
23. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007 132 : 221 35.
24. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 53 : 1617 23.
25. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991 32 : 174 8.
26. Jung WT, Li MS, Goel A, Boland CR. JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer 2008 112 : 1028 36.
27. Leedham SJ, Graham TA, Oukrif D, et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 2009 136 : 542 50.
28. Klotz U, Maier KE, Fischer C, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung 1985 35 : 636 9.
29. Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987 1 : 273 80.
30. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000 14 : 145 53.
31. Sonnenborn U, Janosch D, Dubbert S, Stroff T, Schulze L, Mueller H. Antimutagenic activity of the probiotic E. Coli strain Nissile 1917. J Crohn's and Colitis 2009 3, S136. [Abstract]
32. Simmonds NJ, Millar AD, Blake DR, Rampton DS. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999 13 : 363 72.
33. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003 24 : 443 51.
34. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999 13 : 1397 402.